Estrella Immunopharma, Inc.

Stage 4 · Declining · week 18

As of Oct 22, 2026, Estrella Immunopharma is in Stage 4, the downtrend phase, now in week 18 (since Jun 17, 2026). It closed at $0.73, 76.2% below its 52-week high and below its 200-day average, which is falling.

Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. More about the company

$0.73

+32.18% today

$31.6M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is ESLA early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 41w

S2 13w

S4 18w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 6w → S1 1w → S4 41w → S1 3w → S2 7w → S3 3w → S4 8w → S1 6w → S2 6w → S3 2w → S4 11w → S1 6w → S4 8w → S1 4w → S2 13w → S3 7w → S4 6w → S1 10w → S4 18w current

Total tracked: 166 weeks across 19 stage runs.

ESLA among Biotechnology402nd of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…402	ESLAEstrella Immunopharma, Inc.	Stage 4 · wk 18	18	+54.0%

vs 52W High

-76.2%

$0.31 lo$3.05 hi

76.2% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 18

1w13w26w

Week 18, established downtrend

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-27.2%

200 DMA: $1.00 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

3.39x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+54.0%

-6.8%

-57.5%

YTD

-47.7%

-61.1%

Scan Membership

Breakout Watch

Latest: 2025-01-23

3 appearances in last 60 days. First seen: 2022-06-29.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 18 · Vol 3.39x

2026-10-21S4

Wk 18 · Vol 3.81x

2026-10-20S4

Wk 18 · Vol 0.11x

2026-10-19S4

Wk 18 · Vol 0.94x

2026-10-16S4

Wk 17 · Vol 2.47x

2026-10-15S4

Wk 17 · Vol 137.29x

2026-10-14S4

Wk 17 · Vol 0.44x

2026-10-13S4

Wk 17 · Vol 0.71x

2026-10-12S4

Wk 17 · Vol 2.08x

2026-10-09S4

Wk 16 · Vol 548.60x

2026-10-08S4

Wk 16 · Vol 2.03x

2026-10-07S4

Wk 16 · Vol 1.42x

Moving averages & range

50 DMA

$0.57

200 DMA

$1.00

52W High

$3.05

52W Low

$0.31

5D Low

$0.38

Resistance levels (recent highs)

20d High

$0.73

60d High

$0.76

120d High

$1.53

250d High

$3.05

Next resistance

+4.5%

to 60d High

Dividend Yield

0.00%

P/B -4.2

Estrella Immunopharma: quick answers

What stage is Estrella Immunopharma in?

As of Oct 22, 2026, Estrella Immunopharma (ESLA) is in Stage 4, the downtrend phase. It entered Stage 4 on Jun 17, 2026 and is in week 18. What the four stages mean

Is Estrella Immunopharma in an uptrend?

No. Estrella Immunopharma is in a Stage 4 downtrend. It trades 27.2% below its 200-day average, which is falling.

How far is Estrella Immunopharma from its 52-week high?

Estrella Immunopharma closed at $0.73 on Oct 22, 2026, 76.2% below its 52-week high of $3.05. Its 52-week low is $0.31.

How has Estrella Immunopharma performed over the past year?

As of Oct 22, 2026, Estrella Immunopharma is down 61.1% over the past year and down 47.7% so far in 2026.

Which sector and industry is Estrella Immunopharma in?

Estrella Immunopharma is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.